Measurement of plasma, serum, and platelet serotonin in individuals with high bone mass and mutations in LRP5

Journal of Bone and Mineral Research

Volumn 29, Issue 4, 2014, Pages 976-981

  Lee, Grace S ^a   Simpson, Christine ^a   Sun, Ben Hua ^a   Yao, Chen ^a   Foer, Dinah ^a   Sullivan, Becky ^a   Matthes, Susann ^b,c   Alenina, Natalia ^b   Belsky, Joseph ^a   Bader, Michael ^b   Insogna, Karl L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

Author keywords

DXA; OSTEOBLASTS; OSTEOPOROSIS; OTHER DISEASES AND DISORDERS OF RELATED TO BONE; WNT BETA CATENIN LRP

Indexed keywords

BETA CATENIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; SEROTONIN; WNT PROTEIN; LRP5 PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; BODY MASS; BONE MASS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEMUR NECK; GENE MUTATION; GENE TARGETING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LOSS OF FUNCTION MUTATION; LUMBAR SPINE; MALE; MIDDLE AGED; MINERAL METABOLISM; OSTEOPOROSIS; SEROTONIN BLOOD LEVEL; THROMBOCYTE; THROMBOCYTE POOR PLASMA; BLOOD; BONE DENSITY; GENETICS; MUTATION;

BONE DENSITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-5; MALE; MIDDLE AGED; MUTATION; SEROTONIN;

EID: 84897895220     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2086     Document Type: Article

References (19)

1. Tamai K, Zeng X, Liu C, et al. A mechanism for Wnt coreceptor activation. Mol Cell. 2004; 13 (1): 149-56.
2. Gong Y, Slee RB, Fukai N, et al. Osteoporosis-Pseudoglioma Syndrome Collaborative Group. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001; 107 (4): 513-23.
3. Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002; 346 (20): 1513-21.
4. Van Wesenbeeck L, Cleiren E, Gram J, et al. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet. 2003; 72 (3): 763-71.
5. Whyte MP, Reinus WH, Mumm S., High-bone-mass disease and LRP5. N Engl J Med. 2004; 350 (20): 2096-9; author reply 2096-9.
6. Yadav VK, Ryu JH, Suda N, et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell. 2008; 135 (5): 825-37.
7. Cui Y, Niziolek PJ, MacDonald BT, et al. Lrp5 functions in bone to regulate bone mass. Nat Med. 2011; 17 (6): 684-91.
8. Chang MK, Kramer I, Keller H, et al. Reversing LRP5-dependent osteoporosis and SOST-deficiency induced sclerosing bone disorders by altering WNT signaling activity. J Bone Miner Res. Epub. 2013 Jul 31: DOI: 10.1002/jbmr.2059
9. Goltzman D., LRP5, serotonin, and bone: complexity, contradictions, and conundrums. J Bone Miner Res. 2011; 26 (9): 1997-2001.
10. Frost M, Andersen TE, Yadav V, Brixen K, Karsenty G, Kassem M., Patients with high-bone-mass phenotype owing to Lrp5-T253I mutation have low plasma levels of serotonin. J Bone Miner Res. 2010; 25 (3): 673-5.
11. Frost M, Andersen T, Gossiel F, et al. Levels of serotonin, sclerostin, bone turnover markers as well as bone density and microarchitecture in patients with high-bone-mass phenotype due to a mutation in Lrp5. J Bone Miner Res. 2011; 26 (8): 1721-8.
12. Mödder UI, Achenbach SJ, Amin S, Riggs BL, Melton LJ, Khosla S., Relation of serum serotonin levels to bone density and structural parameters in women. J Bone Miner Res. 2010; 25 (2): 415-22.
13. Estrada K, Styrkarsdottir U, Evangelou E, et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet. 2012; 44 (5): 491-501.
14. Brown PM, Drossman DA, Wood AJ, et al. The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome. Gastroenterology. 2011; 141 (2): 507-16.
15. Inose H, Zhou B, Yadav VK, Guo XE, Karsenty G, Ducy P., Efficacy of serotonin inhibition in mouse models of bone loss. J Bone Miner Res. 2011; 26 (9): 2002-11.
16. Brand T, Anderson GM., The measurement of platelet-poor plasma serotonin: a systematic review of prior reports and recommendations for improved analysis. Clin Chem. 2011; 57 (10): 1376-86.
17. Beck O, Wallén NH, Bröijersén A, Larsson PT, Hjemdahl P., On the accurate determination of serotonin in human plasma. Biochem Biophys Res Commun. 1993; 196 (1): 260-6.
18. Vatassery GT, Sheridan MA, Krezowski AM., Spectrophotofluorometry of serotonin in blood platelets. Clin Chem. 1981; 27 (2): 328-30.
19. Hindberg I, Naesh O., Serotonin concentrations in plasma and variations during the menstrual cycle. Clin Chem. 1992; 38 (10): 2087-9.